What you’re reading on this page.
Lauren Alani writes for biotechnology and pharmaceutical sponsors who carry regulatory accountability for clinical trial data integrity. Each perspective is a structural pattern observed across sponsor engagements between 2019 and 2026, anchored to ICH GCP E6(R3), EMA guidelines, and FDA 21 CFR Part 11. Lauren is Director of Digital Innovation at Seuss+ and chaired the ACDM eDigital Data Management Expert Group from 2019 to 2024. The four core topics covered here are accountability, the regulator-vendor gap, requirements before selection, and data integrity as commercial risk.
Why these four topics
Across the sponsor engagements Lauren has watched succeed, struggle, or surface problems late, the same four structural patterns repeat. They are not industry trends or commentary on individual vendors. They are the points where regulatory expectation, sponsor responsibility, and operational practice meet, and where evidence either accumulates or fails to. Each topic is grounded in a specific regulatory anchor and a repeatable rhetorical sequence: regulatory landscape, common assumption, risk exposure, consequence, structured solution.
The sponsor signed the protocol. The sponsor owns the data. No master service agreement transfers that.
Lauren Alani · on accountability
The data points behind the perspectives
- 15+ years in life sciences (career began at Quintiles in 2009)
- 7+ years in clinical technology across uMotif, Cytel, Novadiscovery, and Seuss+
- ~50% of FDA drug Form 483s cite data integrity concerns; 79% of warning letters reference data integrity issues. (Govzilla, 2014-2018)
- 19% of ~850 sites in the ACRP 2024 global survey cited sponsor-provided technology as a top operational challenge
- 4 ACDM industry whitepapers co-authored; five years (2019-2024) chairing the ACDM eDigital Data Management Expert Group
- ICH GCP E6(R3), EMA guidelines, FDA 21 CFR Part 11, ALCOA+ as the regulatory anchors every perspective is grounded against
How these perspectives are written
Every long-form perspective follows the same logic chain. Step one: the regulatory landscape (where the bar sits). Step two: the common assumption sponsors make about that landscape. Step three: the risk exposure that assumption creates. Step four: the consequence (where it surfaces, on whose timeline). Step five: the structured solution.
The frame is diplomatic, not combative. Lauren’s writing exposes assumptions without scoring points; the questioning method she uses through these pages is a rhetorical structure, not a stylistic choice. Examples are generalised structural patterns drawn from years of sponsor-side observation, never case studies of specific clients. Where regulatory references are made, readers are encouraged to consult the primary source for authoritative content.
Who this is for
The primary audience is biotech and pharmaceutical sponsor leadership: CEOs, founders, heads of clinical operations, heads of data management, heads of quality, and CTOs evaluating clinical systems. Increasingly the audience also includes investors conducting due diligence on clinical-stage assets, where the same data integrity evidence is read with a different question in mind. Secondary readers: CRO leadership, clinical technology vendors, biotech advisors, life sciences media, podcast hosts, and conference programmers.
If you are working through a clinical systems oversight question, a vendor governance review, an inspection-readiness exercise, or a data integrity strategy refresh, the four topics on this page are designed to be useful before you book a conversation, not just after.
Where to read next
Start with the foundational topic, Accountability Cannot Be Delegated, then move through The Regulator-Vendor Gap for the structural context, Requirements Before Selection for the procurement-stage discipline, and Data Integrity Is a Commercial Risk for the commercial framing. Each topic carries its own pull-quotes, key takeaways, and FAQ block. For Lauren’s full bio and working method, see the about page. To bring a perspective to a stage, podcast, panel, or press feature, see media and booking.
Frequently asked
How often does Lauren publish?
Roughly monthly on the four core topics. Each perspective is 1500 to 2500 words, built around the same logic chain (regulatory landscape, common assumption, risk exposure, consequence, structured solution). Subscribers to the monthly newsletter receive an email pointer to each new perspective; the newsletter is one email a month, no pitches.
Can I republish or excerpt these perspectives?
Brief quotations with attribution and a link back are welcomed and encouraged. Press and media may quote with standard journalistic attribution. For longer-form licensing, syndication, or republication in industry publications, contact Gina Dunn, Director of Marketing at Seuss+, at g.dunn@consultseuss.com.
Are these perspectives advisory recommendations for my specific trial?
No. The perspectives are general structural patterns observed across sponsor engagements. They do not constitute regulatory, clinical, or legal advice for any specific trial, asset, or organisation. Sponsors evaluating their own oversight posture should consult their quality leadership and, where appropriate, qualified regulatory or legal counsel.
How does Lauren handle confidentiality with sponsor clients?
Sponsor engagements are confidential by default. Public writing and speaking never reference client names or identifiable details unless explicitly approved for public use. Examples on this page and across the four topics are generalised structural patterns drawn from years of sponsor-side observation, not case studies of specific clients.